<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613128</url>
  </required_header>
  <id_info>
    <org_study_id>PROMISE-OB-18 Pediatric Study</org_study_id>
    <nct_id>NCT04613128</nct_id>
  </id_info>
  <brief_title>The PROMISE Pediatric Study 6 to 11 Years Old</brief_title>
  <official_title>A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Pediatric 6 to 11 Years Old Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Nichols, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center observational study. The study is designed to measure the&#xD;
      clinical effectiveness of elexacaftor, tezacaftor and ivacaftor (ETI) triple combination&#xD;
      therapy in children (6-11 years of old) with one or more copies of the F508del mutation,&#xD;
      study the effects of ETI across a number of CF disease manifestations, and collect specimens&#xD;
      for future research. Subjects in the study will have one &quot;before ETI&quot; visit within 30 days&#xD;
      before initiation of the therapy and five &quot;after ETI&quot; visits over a 24-month follow-up&#xD;
      period. The duration of participation for each subject is 25 months. NOTE: Study will not&#xD;
      begin unless and until FDA approval for ETI in the 6-11 age group is granted.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While nearly 2000 mutations have been described, the most common disease causing CFTR&#xD;
      mutation is F508del, which is found in &gt;85% of patients followed in the US CF Patient&#xD;
      Registry. Two CFTR corrector drugs (elexacaftor and tezacaftor) plus the potentiator&#xD;
      ivacaftor have been developed and approved as a triple combination therapy for CF patients&#xD;
      (12 years old and above) with one or two copies of the F508del mutation. We predict that over&#xD;
      90% of pediatric CF patients (age 6-11 y/o) will be eligible for highly effective CFTR&#xD;
      modulator therapy in the U.S.&#xD;
&#xD;
      The PROMISE Pediatric Study is designed to measure the direct and indirect CFTR dependent&#xD;
      anion secretion by collecting and analyzing clinical research outcomes and biomarkers on&#xD;
      pediatric patients both before and after they begin treatment with ETI. This study will&#xD;
      investigate the impact of ETI across a wide range of CF disease manifestations and organ&#xD;
      systems. While specific biomarkers of special interest have been selected for detailed&#xD;
      analysis in this study, an additional important goal is to collect blood, urine, stool, and&#xD;
      airway epithelial cell specimens for long-term storage in a biorepository to enable future&#xD;
      research. These samples can be made available for research beyond the current scope of work.&#xD;
      The PROMISE Pediatric Study will provide a coordinated collection of clinical research&#xD;
      outcomes data that can be linked with these specimens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sweat Chloride at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Change in sweat chloride from Baseline to 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sweat Chloride at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Change sweat chloride from Baseline to 24 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced expiratory volume at one second (FEV1) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Change in FEV1 from Baseline to 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced expiratory volume at one second (FEV1) at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Change in FEV1 from Baseline to 24 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung Clearance Index (LCI) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Change Lung Clearance Index (LCI) from baseline to 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung Clearance Index (LCI) at 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Change Lung Clearance Index (LCI) from baseline to 24 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Change in weight from Baseline to 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Change in weight from Baseline to 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Change in BMI from Baseline to 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Change in BMI from Baseline to 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystic Fibrosis Questionnaire Revised (CFQ-R) at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Change in CFQ-R (respiratory domain) from Baseline to 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystic Fibrosis Questionnaire Revised (CFQ-R) at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Change in CFQ-R (respiratory domain) from Baseline to 24 months.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Cystic Fibrosis in Children</condition>
  <arm_group>
    <arm_group_label>Pediatric</arm_group_label>
    <description>Cystic Fibrosis pediatric patients (6-11 years old) prescribed ETI CFTR modulator Therapy.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, buffy coat, urine, sputum, oropharyngeal swab (throat swab), stool, sweat&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cystic Fibrosis, 6-11 years old prescribed ETI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written parental informed consent and assent obtained from subject and the subject's&#xD;
             legal guardian.&#xD;
&#xD;
          2. Be willing and able to adhere to the study visit schedule and other protocol&#xD;
             requirements.&#xD;
&#xD;
          3. All genders 6-11 years old on Day 1.&#xD;
&#xD;
          4. Diagnosis of CF.&#xD;
&#xD;
          5. CFTR mutations consistent with the FDA labeled indication for the ETI.&#xD;
&#xD;
          6. Physician intent to prescribe the ETI.&#xD;
&#xD;
          7. Able to attempt the testing and procedures required for this study, as judged by the&#xD;
             investigator.&#xD;
&#xD;
          8. Enrolled in the Cystic Fibrosis Foundation Patient Registry.&#xD;
&#xD;
          9. Clinically stable with no significant changes in health status within the 14 days&#xD;
             prior to Visit 1 (and inclusive of Visit 1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has any other condition that, in the opinion of the Site Investigator/designee, would&#xD;
             preclude informed consent or assent, make study participation unsafe, complicate&#xD;
             interpretation of study outcome data, or otherwise interfere with achieving the study&#xD;
             objectives.&#xD;
&#xD;
          2. Use of any ETI within the 180 days prior to Visit 1.&#xD;
&#xD;
          3. Any acute use of antibiotics (oral, inhaled or IV) or acute use of systemic&#xD;
             corticosteroids within the 14 days prior to Visit 1 (inclusive of Visit 1) for lower&#xD;
             respiratory tract symptoms.&#xD;
&#xD;
          4. Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline,&#xD;
             azithromycin, inhaled tobramycin, Cayston®, Kalydeco, Orkambi®, Symdeko®) within the 4&#xD;
             weeks prior to Visit 1 (inclusive of Visit 1).&#xD;
&#xD;
          5. Use of an investigational agent within the 28 days prior to Visit 1.&#xD;
&#xD;
          6. Use of chronic oral corticosteroids (equivalent to 10 mg. or more per day of&#xD;
             prednisone) within the 28 days prior to Visit 1.&#xD;
&#xD;
          7. Treatment for nontuberculous mycobacterial (NTM) infection, consisting of ≥ two&#xD;
             antibiotics (oral, IV, and/or inhaled) within the 28 days prior to Visit 1.&#xD;
&#xD;
          8. History of lung or liver transplantation,or listing for organ transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Rowe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Nichols, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurel Couture</last_name>
    <phone>206-884-2649</phone>
    <email>laurel.couture@seattlechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Mead</last_name>
    <phone>206-884-7531</phone>
    <email>anna.mead@seattlechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Hathorne</last_name>
      <email>hhathorne@peds.uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Dunn</last_name>
      <email>cedunn@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Cross</last_name>
      <email>mary.cross@childrenscolorado.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larissa Rugg</last_name>
      <email>lrugg@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Bendy</last_name>
      <email>lbendy@iupui.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Teresi</last_name>
      <email>mary-teresi@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britany Zeglin</last_name>
      <email>bzeglin1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital, Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Fowler</last_name>
      <email>Robert.fowler@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Minnesota Cystic Fibrosis Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CF Trials Contact</last_name>
      <email>cftrials@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candy Schmoll</last_name>
      <email>cschmoll@cmh.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Hicks</last_name>
      <email>hickst@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Synger</last_name>
      <email>ashley_synger@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Thornton</last_name>
      <email>Kelly.Thornton@cchmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Hilliard</last_name>
      <email>kathleen.hilliard@uhhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brendan Klein</last_name>
      <email>kleinb@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Howe</last_name>
      <email>klhowe@texaschildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret (Meg) Lessard</last_name>
      <email>margaret.lessard@vcuhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon McNamara</last_name>
      <email>sharon.mcnamara@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophia Chiron Stevens</last_name>
      <email>scstevens@medicine.wisc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Roth</last_name>
      <email>lroth@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>David Nichols, MD</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>CF</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>CFTR Modulator</keyword>
  <keyword>Trikafta</keyword>
  <keyword>Triple Combination Therapy</keyword>
  <keyword>Pediatric</keyword>
  <keyword>ETI</keyword>
  <keyword>elexacaftor/texacaftor/ivacaftor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

